Phase 1 Lupus Trial, Recruiting NCT07215663 Sponsor: Candid Therapeutics Condition: Lupus
Back to Lupus

Phase 1 Lupus Trial, Recruiting

NCT07215663
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old at the time of signing the consent form
  • You have been diagnosed with Systemic Lupus Erythematosus (SLE) using recognised medical classification guidelines
  • Certain specific lupus-related antibodies have been found in your blood tests at screening (confirm with trial site)
  • Your lupus disease activity scores meet a minimum level of severity as measured by a standard lupus scoring tool (confirm with trial site)
  • Your current lupus treatments have not worked well enough for at least 3 months before the screening visit
  • You have been on a stable combination of treatments for a set period before joining
  • If you have active lupus kidney disease specifically, it must be a particular type (Class III or IV) as confirmed by your doctor

Who may not be able to join:

  • Your blood or lab test results at screening fall outside acceptable ranges
  • You currently have an active infection
  • You are taking certain medications that are not allowed in this trial and cannot stop taking them
  • You received a live vaccine within 4 weeks before your screening visit
  • You have another autoimmune disease alongside lupus
  • You have a serious blood-clotting condition called catastrophic antiphospholipid syndrome, either currently or with a known history
  • You have antiphospholipid syndrome or a blood clot that is not well controlled by blood-thinning medication
  • You have a history of a serious brain condition called progressive multifocal leukoencephalopathy
  • You have a history of a primary immune system disorder or an inherited deficiency affecting a part of your immune system called the complement system
  • You have a disease affecting your central nervous system (brain or spinal cord)
  • You have one or more other serious ongoing medical conditions (confirm with trial site)
  • You have been diagnosed with or treated for cancer within the last 5 years
  • You have a serious mental health condition, alcohol or drug dependency, dementia, or any condition that would affect your ability to participate or give informed consent
  • You are unable or unwilling to follow the requirements set out in the trial plan
  • You have had a severe allergic or anaphylactic reaction to a type of medicine called monoclonal antibody therapy, or to any ingredient in the trial drug (cizutamig)
  • You have had an organ transplant or stem cell transplant in the past, or one is planned
  • You have had major surgery requiring general anaesthesia within the last 12 weeks, or major surgery is planned during the trial
  • You are currently pregnant or breastfeeding
  • You are unwilling to use highly effective contraception as required by the trial
  • You are considered part of a vulnerable population, such as being incarcerated

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 17621830227

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Candid Therapeutics
Registry
ClinicalTrials.gov
Start date
4 September 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence and severity of treatment-emergent adverse events through end of study; Changes from baseline in vital signs through end of study: body temperature; Changes from baseline in vital signs through end of study: heart rate; Changes from baseline in vital signs through end of study: respiratory rate; Changes from baseline in vital signs through end of study: blood pressure; Changes from baseline in vital signs through end of study: pulse oximetry; Changes from baseline in ECG parameters through end of study: PR interval; Changes from baseline in ECG parameters through end of study: QRS in...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov